Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 6

Abstract: Introducing a new player in GLP-1-regulated insulin secretion…

Jeffrey R. Schelling & team find inhibition of the fatty acid transport protein FATP2 exerts glucose-lowering effects through GLP-1 secretion by alpha cells:

The figure shows FATP2 expression localizes to pancreatic alpha cells in mouse islets.

1Department of Physiology and Biophysics, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.

2Louis Stokes Cleveland VA Medical Center, VA Northeast Ohio Healthcare System; Department of Ophthalmic Research, Cole Eye Institute, Cleveland, Ohio, USA.

3Department of Medicine and Naomi Berrie Diabetes Center, Vagelos College of Physicians and Surgeons of Columbia University, New York, New York, USA.

Researchers Use Virus To Trace Psilocybin’s Effects Across the Entire Brain

An international collaboration led by Cornell researchers used a combination of psilocybin and the rabies virus to map how – and where – the psychedelic compound rewires the connections in the brain.

Specifically, they showed psilocybin weakens the cortico-cortical feedback loops that can lock people into negative thinking. Psilocybin also strengthens pathways to subcortical regions that turn sensory perceptions into action, essentially enhancing sensory-motor responses.

The findings published Dec. 5 in Cell. The lead author is postdoctoral researcher Quan Jiang.

Microbial molecule that disarms inflammation discovered, offering new diabetes treatment strategy

An international research team has uncovered a surprising ally in the fight against insulin resistance and type 2 diabetes: a microbial metabolite called trimethylamine (TMA). Published in Nature Metabolism, the study reveals that TMA, produced by gut bacteria from dietary choline, can block a key immune pathway and improve blood sugar control.

The study was led by Professor Marc-Emmanuel Dumas at Imperial College London & CNRS together with Prof. Patrice Cani (Imperial & University of Louvain, UCLouvain), Dr. Dominique Gauguier (Imperial & INSERM, Paris) and Prof. Peter Liu (University of Ottawa Heart Institute).

Lower doses of immunotherapy for skin cancer give better results, study suggests

According to a new study, lower doses of approved immunotherapy for malignant melanoma can give better results against tumors, while reducing side effects. This is reported by researchers at Karolinska Institutet in the Journal of the National Cancer Institute.

“The results are highly interesting in oncology, as we show that a lower dose of an immunotherapy drug, in addition to causing significantly fewer side effects, actually gives better results against tumors and longer survival,” says last author Hildur Helgadottir, a researcher at the Department of Oncology–Pathology at Karolinska Institutet, who led the study.

SCFFBXW11 Complex Targets Interleukin-17 Receptor A for Ubiquitin–Proteasome-Mediated Degradation

Interleukin-17 (IL-17) is a pro-inflammatory cytokine that participates in innate and adaptive immune responses and plays an important role in host defense, autoimmune diseases, tissue regeneration, metabolic regulation, and tumor progression. Post-translational modifications (PTMs) are crucial for protein function, stability, cellular localization, cellular transduction, and cell death. However, PTMs of IL-17 receptor A (IL-17RA) have not been investigated. Here, we show that human IL-17RA was targeted by F-box and WD repeat domain-containing 11 (FBXW11) for ubiquitination, followed by proteasome-mediated degradation. We used bioinformatics tools and biochemical techniques to determine that FBXW11 ubiquitinated IL-17RA through a lysine 27-linked polyubiquitin chain, targeting IL-17RA for proteasomal degradation.

Neuralink Patient Controls a Robotic Arm Telepathically! (Interview w/ Nick Wray)

Follow Nick on X: https://twitter.com/Telepath_8

Pre-order linkaChart for free: https://linkaChart.ai/?utm_term=ryan2

Generate AI voice audio via ElevenLabs: https://try.elevenlabs.io/xe894d3yv35h.

Neura Pod is a series covering topics related to Neuralink, Inc. Topics such as brain-machine interfaces, brain injuries, and artificial intelligence will be explored. Host Ryan Tanaka synthesizes information, shares the latest updates, and conducts interviews to easily learn about Neuralink and its future.

Sign up for Neuralink’s Patient Registry: https://neuralink.com/trials/

Join the Neuralink team: https://neuralink.com/careers/

Continue reading “Neuralink Patient Controls a Robotic Arm Telepathically! (Interview w/ Nick Wray)” | >

For those living with dementia, new study suggests shingles vaccine could slow the disease

An unusual public health policy in Wales may have produced the strongest evidence yet that a vaccine can reduce the risk of dementia. In a new study led by Stanford Medicine, researchers analyzing the health records of Welsh older adults discovered that those who received the shingles vaccine were 20% less likely to develop dementia over the next seven years than those who did not receive the vaccine.

The remarkable findings, published April 2 in Nature, support an emerging theory that viruses that affect the nervous system can increase the risk of dementia. If further confirmed, the new findings suggest that a preventive intervention for dementia is already close at hand.

In a follow-up study published Dec. 2 in Cell, the researchers found that the vaccine may also benefit those already diagnosed with dementia by slowing the progress of the disease.

/* */